- Home
- BTE vs CADL Comparison
BTE vs CADL Comparison
Compare BTE & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTE
- CADL
- Stock Information
- Founded
- BTE 1993
- CADL 1999
- Country
- BTE Canada
- CADL United States
- Employees
- BTE N/A
- CADL N/A
- Industry
- BTE Meat/Poultry/Fish
- CADL Biotechnology: Pharmaceutical Preparations
- Sector
- BTE Consumer Staples
- CADL Health Care
- Exchange
- BTE Nasdaq
- CADL Nasdaq
- Market Cap
- BTE 1.4B
- CADL 250.0M
- IPO Year
- BTE N/A
- CADL 2021
- Fundamental
- Price
- BTE $1.88
- CADL $6.24
- Analyst Decision
- BTE Hold
- CADL Strong Buy
- Analyst Count
- BTE 1
- CADL 5
- Target Price
- BTE $5.50
- CADL $21.40
- AVG Volume (30 Days)
- BTE 46.1M
- CADL 1.1M
- Earning Date
- BTE 07-28-2025
- CADL 08-12-2025
- Dividend Yield
- BTE 3.40%
- CADL N/A
- EPS Growth
- BTE N/A
- CADL N/A
- EPS
- BTE 0.28
- CADL N/A
- Revenue
- BTE $2,327,227,884.00
- CADL N/A
- Revenue This Year
- BTE $3.43
- CADL N/A
- Revenue Next Year
- BTE N/A
- CADL N/A
- P/E Ratio
- BTE $6.78
- CADL N/A
- Revenue Growth
- BTE 10.55
- CADL N/A
- 52 Week Low
- BTE $1.36
- CADL $3.79
- 52 Week High
- BTE $3.84
- CADL $14.60
- Technical
- Relative Strength Index (RSI)
- BTE 50.80
- CADL 68.08
- Support Level
- BTE $1.84
- CADL $5.78
- Resistance Level
- BTE $1.95
- CADL $6.42
- Average True Range (ATR)
- BTE 0.09
- CADL 0.36
- MACD
- BTE -0.00
- CADL 0.19
- Stochastic Oscillator
- BTE 44.44
- CADL 99.56
About BTE Baytex Energy Corp
Baytex Energy Corp is an oil and gas company. Geographically, the group operates in Canada and the United States. The company derives a majority of revenue from Canada. Its Canada segment includes the exploration, development, and production of crude oil and natural gas in Western Canada.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.